ERBB2 and breast carcinoma: Triple-negative (ER-, PR-, and HER2-) breast cancer (TNBC), a heterogeneous disease, comprises approximately 10–20% of all breast cancers [5–8] and can be further grouped into distinct subtypes by gene expression profiling [9].